Abstract

Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions, were integrated with detailed whole-tumor and regional histopathological analysis. Tumors with predominantly high-grade patterns showed increased chromosomal complexity, with higher burden of loss of heterozygosity and subclonal somatic copy number alterations. Individual regions in predominantly high-grade pattern tumors exhibited higher proliferation and lower clonal diversity, potentially reflecting large recent subclonal expansions. Co-occurrence of truncal loss of chromosomes 3p and 3q was enriched in predominantly low-/mid-grade tumors, while purely undifferentiated solid-pattern tumors had a higher frequency of truncal arm or focal 3q gains and SMARCA4 gene alterations compared with mixed-pattern tumors with a solid component, suggesting distinct evolutionary trajectories. Clonal evolution analysis revealed that tumors tend to evolve toward higher-grade patterns. The presence of micropapillary pattern and ‘tumor spread through air spaces’ were associated with intrathoracic recurrence, in contrast to the presence of solid/cribriform patterns, necrosis and preoperative circulating tumor DNA detection, which were associated with extra-thoracic recurrence. These data provide insights into the relationship between LUAD morphology, the underlying evolutionary genomic landscape, and clinical and anatomical relapse risk.

Original languageEnglish
Pages (from-to)833-845
Number of pages12
JournalNature Medicine
Volume29
Issue number4
Early online date12 Apr 2023
DOIs
Publication statusPublished - 12 Apr 2023

Bibliographical note

Funding Information:
The TRACERx study (NCT01888601) is sponsored by University College London (UCL/12/0279) and has been approved by an independent Research Ethics Committee (13/LO/1546). TRACERx is funded by Cancer Research UK (CRUK; C11496/A17786) and coordinated through the CRUK & UCL Cancer Trials Centre, which has a core grant from CRUK (C444/A15953). We gratefully acknowledge the participants and relatives who participated in the TRACERx study. We thank all site personnel, investigators, funders and industry partners that supported the generation of the data within this study. In particular, we acknowledge the support of Scientific Computing, the Advanced Sequencing Facility and Experimental Histopathology departments at the Francis Crick Institute. This work was also supported by the CRUK Lung Cancer Centre of Excellence and the CRUK City of London Centre Award (C7893/A26233) and the UCL Experimental Cancer Medicine Centre. BioRender aided in the generation of Figs. and and Extended Data Figs. and . T.K. is supported by the JSPS Overseas Research Fellowships Program (202060447). D.A.M. is supported by the CRUK Lung Cancer Centre of Excellence (C11496/A30025). M.A.B. is supported by CRUK, the Rosetrees Trust and the Francis Crick Institute. T.B.K.W. is supported by the Francis Crick Institute, as well as the Marie Curie ITN Project PLOIDYNET (FP7-PEOPLE-2013, 607722), Breast Cancer Research Foundation, Royal Society Research Professorships Enhancement Award (RP/EA/180007) and the Foulkes Foundation. A. Huebner is supported by CRUK. A.M.F. is supported by Stand Up To Cancer (SU2C-AACR-DT23-17). H.Z. is supported by the China Scholarship Council for a 4-year PhD study and the Breast Cancer Research Foundation. F.G.-V. is supported by Generalitat Valenciana fellowships program (APOSTD/2021/168). M.D. is supported by CRUK and the Lung Cancer Centre of Excellence. C.M.-R. is supported by the Rosetrees Trust (M630) and Wellcome Trust. E.C. is supported by CRUK (TRACERx (C11496/A17786)) and the Francis Crick Institute. K.S.S.E. was supported by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 838540 and the Royal Society (RF\ERE\210216). S.H. is supported by CRUK and the Rosetrees Trust. C.T.H. has received funding from NIHR University College London Hospitals Biomedical Research Centre. S.Z. is a CRUK Career Development Fellow (award ref. RCCCDF-Nov21\100005) and is supported by Rosetrees Trust (grant ref. M917) and CRUK UCL Centre Non-Clinical Training Award (CANTAC721\100022). K.L. is funded by the UK Medical Research Council (MR/P014712/1 and MR/V033077/1), Rosetrees Trust and Cotswold Trust (A2437) and CRUK (C69256/A30194). N.J.B. is a fellow of the Lundbeck Foundation (R272-2017-4040) and acknowledges funding from Aarhus University Research Foundation (AUFF-E-2018-7-14) and the Novo Nordisk Foundation (NNF21OC0071483).E.L.C., J.D. and P.V.L. are supported by the Francis Crick Institute, which receives its core funding from CRUK (CC2008), the UK Medical Research Council (CC2008) and the Wellcome Trust (CC2008). P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation’s support toward the establishment of the Francis Crick Institute. P.V.L. is a CPRIT Scholar in Cancer Research and acknowledges CPRIT grant support (RR210006). P.S.A.’s laboratory work is supported by grants from the National Institutes of Health (P30 CA008748, R01 CA236615, R01 CA235667 and U01 CA214195), the US Department of Defense (CA180889 and CA200437), the DallePezze Foundation and the Derfner Foundation. P.S.A.’s laboratory receives research support from ATARA Biotherapeutics. D.R.J. is supported by National Institutes of Health grants R01CA217169, R01CA240472 and P30 CA008748 and the Hamilton Family Foundation. T.M. is supported by the UK National Institute of Health Research University College London Hospital Biomedical Research Centre. N.M. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (grant no. 211179/Z/18/Z) and also receives funding from CRUK, Rosetrees and the National Institute for Health Research (NIHR) Biomedical Research Centre at University College London Hospitals and the CRUK University College London Experimental Cancer Medicine Centre. M.J.-H. is a CRUK Career Establishment Awardee and has received funding from CRUK, IASLC International Lung Cancer Foundation, Lung Cancer Research Foundation, Rosetrees Trust, UKI NETs and NIHR University College London Hospitals Biomedical Research Centre. C.S. is a Royal Society Napier Research Professor (RSRP\R\210001). C.S. is supported by the Francis Crick Institute that receives its core funding from CRUK (CC2041), the UK Medical Research Council (CC2041), and the Wellcome Trust (CC2041). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. C.S. is funded by CRUK (TRACERx (C11496/A17786), PEACE (C416/A21999) and CRUK Cancer Immunotherapy Catalyst Network); CRUK Lung Cancer Centre of Excellence (C11496/A30025); the Rosetrees Trust, Butterfield and Stoneygate Trusts; NovoNordisk Foundation (ID16584); Royal Society Professorship Enhancement Award (RP/EA/180007); NIHR University College London Hospitals Biomedical Research Centre; the CRUK University College London Centre; Experimental Cancer Medicine Centre; the Breast Cancer Research Foundation (US); and The Mark Foundation for Cancer Research Aspire Award (grant 21-029-ASP). This work was supported by a Stand Up To Cancer‐LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant (grant no. SU2C-AACR-DT23-17 to S. M. Dubinett and A. E. Spira). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. C.S. is in receipt of an ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 835297).

Publisher Copyright:
© 2023, The Author(s) under exclusive license to Springer Nature America, Inc.

Keywords

  • Adenocarcinoma of Lung/genetics
  • Adenocarcinoma/genetics
  • DNA Helicases
  • Disease Progression
  • Humans
  • Lung Neoplasms/genetics
  • Neoplasm Recurrence, Local/pathology
  • Nuclear Proteins
  • Transcription Factors

Fingerprint

Dive into the research topics of 'Evolutionary characterization of lung adenocarcinoma morphology in TRACERx'. Together they form a unique fingerprint.

Cite this